See more : Essity AB (publ) (ETTYF) Income Statement Analysis – Financial Results
Complete financial analysis of Ascelia Pharma AB (publ) (ACE.ST) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ascelia Pharma AB (publ), a leading company in the Biotechnology industry within the Healthcare sector.
- C.S. Lumber Co., Inc (7808.T) Income Statement Analysis – Financial Results
- Prestige Cars International, Inc. (PREC) Income Statement Analysis – Financial Results
- Rich Goldman Holdings Limited (0070.HK) Income Statement Analysis – Financial Results
- SK3 Group, Inc. (SKTO) Income Statement Analysis – Financial Results
- Saudi Manpower Solutions Co. (1834.SR) Income Statement Analysis – Financial Results
Ascelia Pharma AB (publ) (ACE.ST)
About Ascelia Pharma AB (publ)
Ascelia Pharma AB (publ), a biotech company, operates as an oncology-focused orphan drug development company in Sweden. It is developing Mangoral, a novel non-gadolinium contrast agent, which is in Phase 3 for use in MRI-scans of the liver; and Oncoral, a novel oral chemotherapy tablet, which is in Phase 2 for the treatment of gastric cancer. It has a clinical collaboration agreement with Taiho Oncology, Inc. for the development of Oncoral in combination with LONSURF. Ascelia Pharma AB (publ) was founded in 2000 and is headquartered in Malmö, Sweden.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.05M | 3.89M | 8.72M | 825.00K | 62.00K | 2.51M | 0.00 |
| Gross Profit | -1.05M | -3.89M | -8.72M | -825.00K | -62.00K | -2.51M | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 81.27M | 88.23M | 75.08M | 64.76M | 26.92M | 15.57M | 9.37M |
| General & Administrative | 19.77M | 10.73M | 8.81M | 8.89M | 17.99M | 6.59M | 16.37M |
| Selling & Marketing | 10.44M | 14.93M | 13.20M | 10.23M | 1.45M | 0.00 | 0.00 |
| SG&A | 30.21M | 25.66M | 22.01M | 19.11M | 8.32M | 6.59M | 16.37M |
| Other Expenses | -564.00K | 29.89M | 32.09M | 9.38M | -1.45M | 12.46M | -1.02M |
| Operating Expenses | 110.91M | 143.78M | 129.17M | 93.26M | 36.68M | 34.62M | 24.71M |
| Cost & Expenses | 110.91M | 147.67M | 137.90M | 93.26M | 36.74M | 37.13M | 24.71M |
| Interest Income | 1.32M | 635.00K | 10.00K | 27.00K | 59.00 | 76.00K | 10.00K |
| Interest Expense | 14.00K | 48.00K | 77.00K | 13.00K | 0.00 | 33.00K | 18.00K |
| Depreciation & Amortization | 1.05M | 1.05M | 1.03M | 825.00K | 62.00K | -127.00K | 24.67M |
| EBITDA | -108.56M | -132.06M | -128.42M | -98.91M | -39.93M | -37.52M | -71.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -110.91M | -147.01M | -137.95M | -93.43M | -36.74M | -37.39M | -24.71M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.31M | 13.85M | 8.43M | -6.32M | -3.25M | -160.00K | -30.00K |
| Income Before Tax | -109.61M | -133.16M | -129.52M | -99.75M | -40.00M | -37.55M | -24.74M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -319.00K | -1.93M | -3.62M | -1.05M | -90.00K | -417.00K | -351.00K |
| Net Income | -109.29M | -131.22M | -125.90M | -98.70M | -39.91M | -37.13M | -24.39M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.24 | -3.90 | -3.82 | -3.76 | -1.83 | -2.16 | -1.08 |
| EPS Diluted | -3.24 | -3.90 | -3.82 | -3.76 | -1.83 | -2.16 | -1.08 |
| Weighted Avg Shares Out | 33.72M | 33.67M | 32.96M | 26.27M | 21.80M | 17.17M | 22.61M |
| Weighted Avg Shares Out (Dil) | 33.72M | 33.67M | 32.96M | 26.27M | 21.80M | 17.17M | 22.61M |
Source: https://incomestatements.info
Category: Stock Reports